• Home

  • HEALTH CARE

  • HEALTHY LIFESTYLE

  • HYGIENE

  • COSMETICS

  • FOR HIM

  • PREGNANCY AND MOTHERHOOD

  • CHILD

    2. HEALTH CARE
    3. Liberatti 0.02mg/3mg, 28 tablets — Made in Spain — Free Delivery

    Liberatti 0.02mg/3mg, 28 tablets — Made in Spain — Free Delivery


    Brand: Laboratorios Leon Farma
    Product Code: Liberatti
    Availability: 2 - 3 Days
    $26.50
    Add to Cart

    Product description 

    Liberatti tablets are indicated for oral contraception.

    Compound

    Active ingredients: ethinylestradiol, drospirenone;
    1 coated tablet (pink) contains ethinylestradiol 0.02 mg, drospirenone 3 mg;
    Excipients: lactose, pregelatin starch (corn), povidone K-30, sodium croscarmellose, polysorbate 80, magnesium stearate, shell: opadry® II pink (partially hydrogenated polyvinyl alcohol, titanium dioxide (E 171), macrogol 3350, talc (E 553b), iron oxide yellow (E172), iron oxide red (E172), iron oxide black (E172)).
    1 coated tablet, placebo (white) contains anhydrous lactose, povidone K-30, magnesium stearate, shell: opadry® II white (partially hydrogenated polyvinyl alcohol, titanium dioxide (E171), macrogol 3350, talc (E553b)).

    Contraindications

    • Combined hormonal contraceptives (CHCs) should not be used if any of the following conditions are present. If any of these conditions occur for the first time during the use of CHC, the preparation should be stopped immediately.
    • the presence or risk of developing venous thromboembolism (VTE);
    • the presence or risk of developing arterial thromboembolism (ATE);
    • diabetes mellitus with vascular complications;
    • severe arterial hypertension;
    • severe dyslipoproteinemia;
    • the presence of severe liver disease at present or in history, until the indicators of liver function have returned to the normal range;
    • severe renal failure or acute renal failure;
    • the presence of liver tumors at present or in history (benign or malignant);
    • known or suspected malignant tumors (for example, genital or mammary glands), dependent on sex hormones;
    • vaginal bleeding of unknown etiology;
    • hypersensitivity to the active substances or to any of the components of the preparation;

    Mode of application

    Tablets should be taken daily according to the order indicated on the package, at about the same time, with a small amount of liquid if necessary. Tablets should be taken continuously. The preparation is taken 1 tablet / day for 28 days in a row. Taking tablets from each subsequent package should be started the next day after the end of the previous package. As a rule, withdrawal bleeding begins on the 2-3rd day after the start of the placebo pills (last row) and may not end before the start of the pills from the next pack.

    Application features

    pregnant
    Contraindicated.
    Children
    The preparation is indicated for use as prescribed by a doctor only after the onset of stable menstruation.
    Overdose
    So far, there are no data from clinical studies regarding the overdose of Liberatti tablets. Based on general experience with combined oral contraceptives, overdose may cause nausea, vomiting, or, in young girls, vaginal bleeding. There is no specific antidote; treatment should be symptomatic.

    Side effects

    Mental disorders. Emotional lability.
    Nervous system. Headache.
    From the gastrointestinal tract. Nausea.
    From the reproductive system and mammary glands. Soreness of the mammary glands, metrorrhagia, amenorrhea.

    Interaction

    COCs may affect the metabolism of certain active substances. Accordingly, plasma and tissue concentrations may either increase (eg, cyclosporine) or decrease (eg, lamotrigine).
    Based on in vivo interaction studies in female volunteers taking omeprazole, simvastatin and midazolam as substrate markers, it was found that a clinically significant interaction of drospirenone at a dose of 3 mg with other preparations that are induced by cytochrome P450 is unlikely.
    Clinical data suggest that ethinylestradiol inhibits the clearance of CYP1A2 substrates, which in turn causes a slight (eg, theophylline) or moderate (eg, tizanidine) increase in their plasma concentrations.

    Storage conditions

    Store at a temperature not exceeding 30°C.
    Keep out of the reach of children.
    Shelf life - 3 years.

    There are no reviews for this product.
    VEV Healthcare Store © 2017